Diabetes therapy

Diabetes therapy

Biocon Biologics Expands Strategic Collaboration with Civica to Increase Access to Affordable Insulins in the United States

Biocon Biologics Ltd., a leading global biosimilars company, has announced an expansion of its strategic collaboration with Civica, Inc. to include a new Insulin Glargine medicine. This multi-year agreement aims to increase the supply of high-quality, affordable insulins in the United States, benefiting patients with diabetes. The agreement establishes an